MedTrace Logo

Phosphorus 32 in Treating Patients With Glioblastoma Multiforme

NCT00004129 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.

Conditions

Interventions

RADIATION

brachytherapy

RADIATION

phosphorus P32

Sponsors & Collaborators

  • Center for Molecular Medicine

    lead OTHER

Principal Investigators

  • Stanley E. Order, MD, ScD, FACR · Center for Molecular Medicine

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004129 on ClinicalTrials.gov